BioNTech Shutters Three German Plants as Founders Chart a New Venture
Published on 10/07/2026 at 10:31 | Editorial boerse-global.de
BioNTech is dismantling parts of the industrial machine it built during the pandemic, and the shake-up extends well beyond the factory floor. The Mainz-based biotech has confirmed it will close three German production sites after failing to find buyers for the facilities, a decision that puts as many as 1,860 jobs on the line.
The closures will unfold in stages. Tübingen is first in line, with operations winding down by the end of 2027. Marburg follows in early 2028, and Idar-Oberstein is slated to go dark by the end of 2028. Reuters reported the plans, which also sweep in former CureVac properties as part of a broader capacity consolidation. Management is responding to waning demand for vaccines and reshaping its manufacturing base around the company's forward-looking priorities — a painful blow to the affected regions, but one that should free up breathing room on fixed operating costs.
A New Name in the Founders' Orbit
While the plants wind down, the company's founders are moving in a different direction. U?ur ?ahin and Özlem Türeci have established a new pharmaceutical venture in Mainz under the name Arife, a company spokesperson confirmed. Both intend to remain BioNTech shareholders even as they build out the new entity.
The founders' new project comes as the CEO continues to trim his personal stake. ?ahin sold 17,000 ordinary shares on each of two trading days, according to a mandatory filing with the US Securities and Exchange Commission. The transactions were executed under a Rule 10b5-1 trading plan established on June 3, 2026 — an arrangement that lets executives sell on a pre-set schedule, insulating them from any suggestion that the moves reflect a short-term read on the business.
Should investors sell immediately? Or is it worth buying BioNTech?
That pattern has been in place for a while. Under the same June 3 plan, 66,000 ordinary shares were offloaded at the end of September, and SEC filings show another 17,000-share sale through a similar arrangement. Such pre-programmed disposals are typically treated as orderly portfolio management rather than a signal about management's operational outlook.
Market Takes the Restructuring in Stride
Investors have absorbed the news without much drama. The stock traded at EUR 85.30 on Wednesday, eking out a modest gain of 0.2% for the day. That quiet session followed a 2.1% decline the prior day, when the shares closed at EUR 85.15 — a dip that came with no clear company- or sector-specific trigger, according to media reports.
Over a 30-day horizon, the shares are down 4.4%, stuck in a consolidation phase as directional catalysts dry up. Even so, the stock is holding just above its 200-day moving average of EUR 84.65, a level that offers some technical support.
The broader picture has been taking shape for weeks. More than a month ago, BioNTech announced the German plant closures; roughly two weeks later, word surfaced of the founders' retreat. About three weeks back came updated Gotistobart data alongside the supervisory board's proposal to appoint KPMG as auditor — signs of a company retooling its structures while pushing its oncology pipeline forward.
For shareholders, two threads now run in parallel: the mechanical, pre-arranged nature of the insider sales, and the market's focus on the longer-term realignment. Absent fresh operational signals, the stock looks set to move in step with the wider sector for the time being.
Ad
BioNTech Stock: New Analysis - 7 October
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
